Results 251 to 260 of about 2,974,682 (398)

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease

David Greeley, Marshall Nash, Brad Herskowitz, Fred Kim, James Rock, Niels D. Prins, SangYun Kim, Tianyang Xi, Jonathan A. Busam, Benoit Tete, Jai Jun Choung, Sharon J. Sha   +11 more
openalex   +1 more source

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp, April W. Armstrong, Tomokazu Koresawa, Kazunari Otake, Masayuki Hirata, Akiko Kano   +5 more
wiley   +1 more source

Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics

, 2003
Euikyung Kim, Hyung-Ok Chun, Sung-Hak Jung, Jong‐Hoon Kim, Jae‐Mok Lee, Byung-Chul Suh, Myung Xik Xiang, Chung K. Rhee   +7 more
openalex   +1 more source

Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.

Proceedings of the National Academy of Sciences of the United States of America, 1995
C. Genain, T. Roberts, R. Davis, My-Hoa Nguyen, A. Uccelli, D. Faulds, Yi Li, J. Hedgpeth, S. Hauser   +8 more
semanticscholar   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Improved survival with phosphodiesterase-5 inhibitor use in men with male-predominant cancers: real-world large database study. [PDF]

Front Oncol
Uralov D, Harrington SR, Samarah H, Walia AS, Aweeda M, Mustafa MU, Kumar P, Briskin A, Jackson J, Mastrolonardo EV, Luginbuhl AJ.   +10 more
europepmc   +1 more source

Pharmacological characterization of the neonatally sensitized rabbit model and effects of a novel phosphodiesterase (PDE) 4 inhibitor [PDF]

, 1998
Neil Gozzard, Bernadette Hughes, Graham J. Warrellow, Gerry Higgs   +3 more
openalex   +1 more source

Engineering the bacterial nutrition strategy to control plant diseases

Journal of Integrative Plant Biology, EarlyView.
This commentary on Wang et al. (2025) and Phan et al. (2025) highlights previously undiscovered Xanthomonas pathways for nutrition acquisition, explains how Xanthomonas bacteria hijack host molecular machinery through their effector proteins, and discusses how these studies can be used to develop new disease resistance mechanisms.
Muhammad Arslan Mahmood, Shahid Mansoor, Muhammad Naveed Aslam   +2 more
wiley   +1 more source

Unveiling of phosphodiesterase-5 hot residues binding to xanthine derivatives for erectile dysfunction therapy: A computational drug repurposing approach. [PDF]

PLoS One
Elzupir AO, Almahmoud SAJ.
europepmc   +1 more source